The DurAVR transcatheter heart valve was evaluated in a first-in-human study for treating symptomatic severe aortic stenosis. The study demonstrated a good safety profile and promising haemodynamic performance sustained at 1 year. #EAPCI #EUROPCR ow.ly/Lvya50OsBmL

.Anteris Technologies shares data from the DurAVR THV FIH study. It shows sustained haemodynamic performance at 1 year. Presented by Susheel Kodali, MD with simultaneous publication at #EuroPCR. #TAVR #TAVI Sponsored post by Anteris Technologies

It was a pleasure to work along João Cavalcante Chris Meduri, MD MPH and others on this study: Early safety and feasibility of a first-in-class biomimetic transcatheter aortic valve (DurAVR) via EuroIntervention Anteris Technologies eurointervention.pcronline.com/article/early-…

New biomimetic #TAVR valve linked to strong performance after 1 year Anteris Technologies João Cavalcante Chris Meduri, MD MPH Pankaj Garg EuroIntervention Susheel Kodali, MD Columbia Valve Center Columbia Medicine #DurAVR #cardiology #cardiotwitter ow.ly/kNc150Ow1ol

Excited to showcase the company’s progress over the last 12 months and our future #ProudtobeAnteris #AGM #ASX $AVR #Anteristech

#Anteristech proudly presents Wayne Paterson at 2022 Annual General Meeting. To watch the full event, click here: links.anteristech.com/3ovW53t #ProudtobeAnteris $AVR #cardiology #TAVR #TAVI #innovation #AGM

In this episode of the MassDevice Fast Five medtech news podcast we discussed: - Henry Schein  & #Medpod - Inspire Sleep Apnea Innovation - Anteris Technologies - Augmedics - Abbott LISTEN HERE: massdevice.com/fast-five-abbo… #Healthcare #Transcatheter #Aortic #MedicalDevice #Telehealth #HeartValve

#AnterisTech is pleased to announce DurAVR™ FIH abstract has been published in Heart Lung and Circulation as part of the 71st Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand, 3-6 August 2023, Adelaide, Australia. Visit: heartlungcirc.org/article/S1443-…

#AnterisTech announces first patients successfully treated in #DurAVR THV US Early Feasibility Study Azeem Latib performed the cases at Montefiore Health System $AVR #TAVR #TAVI #Innovation #CardioTwitter #cardiology #heart #doctor #cardiac Full Details: links.anteristech.com/3Ym60G7

We are pleased with the excellent results achieved by Dr. Latib and the team at Montefiore. We look forward to sharing the results at TCT 2023. businesswire.com/news/home/2023…

Anteris’ starts US trial for DurAVR transcatheter heart valve medicaldevice-network.com/news/anteris-s… via Medical Technology & Medical Device Network

#AnterisTech announces second valve-in-valve case with #DurAVR THV and achieves phenomenal results. Janar Sathananthan performed the procedure at Saint Paul’s Hospital, Vancouver $AVR #TAVR #TAVI #Innovation #CardioTwitter #cardiology Full Details: links.anteristech.com/3pz67kg\

Congratulations and thank you to Dr. Samir Kapadia Dr. Amar Krishnaswamy, Dr. Rishi Puri and the entire team at Cleveland Clinic for enrolling their first patients in the DurAVR THV US Early Feasibility Study. #DurAVR #TAVR #TAVI #AnterisTech #aorticstenosis #proudtobeanteris

#AnterisTech will be sharing new data from the DurAVR™ US Early Feasibility Study at #TCT2023. Presented by Azeem Latib. Let’s move the conversation forward in TAVR. Sign up to receive clinical updates: links.anteristech.com/3S0KANs

It's been an exciting day of TAVR data at #TCT2023, with major updates on #TAVR studies! It's clear that valve performance matters. Tune in this afternoon for DurAVR™ THV US EFS discharge data -- moving the conversation forward with paradigm-shifting hemodynamic performance!

Great presentation today by Dr Latib on our US EFS study. Hemodynamics, EOAs, DVI results are unprecedented. #hemodynamicsmatter #valvedesignmatters #proudtobeanteris

Last week Stephanie Sellers presented bench testing results from the novel DurAVR™ THV at #TCT2023. DurAVR demonstrated superior hemodynamic performance in Redo-TAVR procedures. Learn more about DurAVR here: links.anteristech.com/3S0KANs #TAVR #TAVI #innovation #AnterisTech

Novartis pays Legend $100M upfront to give solid tumor CAR-T the T-Charge treatment fiercebiotech.com/biotech/novart…

Consumerism expected to play a major role in AI regulation bioworld.com/articles/70268… #medtech AFDO Regulatory Affairs Professionals Society

Further evidence that DurAVR™ the first in class biomimetic valve built on the Adapt® tissue platform is showing exceptional results due to its novel valve design and superior tissue science whilst maintaining more predictable delivery with a novel BE platform #valvedesign